This company listing is no longer active
Aceragen Management
Management criteria checks 3/4
Aceragen's CEO is John Taylor, appointed in Sep 2022, he has a tenure of less than a year. His total yearly compensation is $444.06K , comprised of 17.5% salary and 82.5% bonuses, including company stock and options. He directly owns 17.45% of the company’s shares, worth $558.40K. The average tenure of the management team and the board of directors is 4.1 years and 4.3 years respectively.
Key information
John Taylor
Chief executive officer
US$444.1k
Total compensation
| CEO salary percentage | 17.48% |
| CEO tenure | less than a year |
| CEO ownership | 17.5% |
| Management average tenure | 4.1yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$444k | US$78k | -US$23m |
Compensation vs Market: John's total compensation ($USD444.06K) is below average for companies of similar size in the US market ($USD760.57K).
Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.
CEO
John Taylor (52 yo)
Mr. John C. Taylor serves as President, Chief Executive Officer and Director since September 28, 2022 at Aceragen, Inc. He was Chief Executive Officer of Spyryx Biosciences, Inc since December 2013 and ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Associate Director of Human Resources | no data | no data | no data | |
| Director of Human Resources | no data | no data | no data | |
| Senior Vice President of Technical Operations | no data | no data | no data | |
| Global Head of Quality | no data | no data | no data | |
| Medical Director & Global Clinical Lead for Oncology | no data | no data | no data | |
| Advisor | 4.1yrs | US$993.93k | no data | |
| Adviser | no data | US$986.13k | no data |
Experienced Management: ACGN's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Independent Director | 4.3yrs | US$89.43k | 0.26% $ 8.4k | |
| Chair of the Board of Directors | 8.7yrs | US$1.43m | 0.10% $ 3.2k | |
| Independent Director | less than a year | US$11.88k | no data | |
| Independent Director | 7.6yrs | US$66.24k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$60.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisor Board | no data | no data | 14.31% $ 458.0k |
Experienced Board: ACGN's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/23 09:49 |
| End of Day Share Price | 2023/08/21 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aceragen, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Huidong Wang | Barclays |
| Michael King | Citizens JMP Securities, LLC |